FOLD Stock Overview
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Amicus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.54 |
| 52 Week High | US$14.57 |
| 52 Week Low | US$9.70 |
| Beta | 0.76 |
| 1 Month Change | -8.67% |
| 3 Month Change | -16.61% |
| 1 Year Change | -8.82% |
| 3 Year Change | 3.03% |
| 5 Year Change | -21.40% |
| Change since IPO | -26.96% |
Recent News & Updates
Recent updates
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough
Mar 27
Amicus Therapeutics: Expect Improved Commercial Momentum In 2024
Feb 29Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk
Dec 19Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Jul 06Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors
May 14Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?
Mar 23We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt
Dec 06Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Aug 25Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding
Aug 10Amicus Therapeutics Q2 2022 Earnings Preview
Aug 03Is Amicus Therapeutics (NASDAQ:FOLD) Weighed On By Its Debt Load?
May 06Amicus Therapeutics: An Inflection Point In Growth
Apr 27Amicus: July 29 PDUFA Makes It A Hold
Apr 11Amicus Therapeutics: PDUFA In 6 Months
Jan 28Shareholder Returns
| FOLD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.09% | 1.0% | 1.2% |
| 1Y | -8.8% | 0.7% | 24.9% |
Price Volatility
| FOLD volatility | |
|---|---|
| FOLD Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FOLD's share price has been volatile over the past 3 months.
Volatility Over Time: FOLD's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 517 | Brad Campbell | amicusrx.com |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.
Amicus Therapeutics, Inc. Fundamentals Summary
| FOLD fundamental statistics | |
|---|---|
| Market cap | US$3.16b |
| Earnings (TTM) | -US$151.58m |
| Revenue (TTM) | US$399.36m |
7.8x
P/S Ratio-20.5x
P/E RatioIs FOLD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FOLD income statement (TTM) | |
|---|---|
| Revenue | US$399.36m |
| Cost of Revenue | US$37.33m |
| Gross Profit | US$362.03m |
| Other Expenses | US$513.61m |
| Earnings | -US$151.58m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.51 |
| Gross Margin | 90.65% |
| Net Profit Margin | -37.96% |
| Debt/Equity Ratio | 242.1% |
How did FOLD perform over the long term?
See historical performance and comparison